A tragic incident in Nagpur has raised serious public health concerns after a 3-year-old girl from Chhindwara, Madhya Pradesh, died following the consumption of Coldrif cough syrup. The child was admitted to a Nagpur hospital but could not be saved, increasing the death toll from this spurious cough syrup in Madhya Pradesh to 24 as of October 16, 2025. Investigations have linked the fatalities to Sresan Pharmaceuticals, the manufacturer of the contaminated syrup. Authorities have arrested a woman chemical analyst associated with the company in connection with the case. The arrest is part of a wider crackdown on negligence and illegal practices surrounding the production and quality control of medicines. The Health Department of Madhya Pradesh, in coordination with the Food and Drug Administration (FDA), is conducting a thorough probe to identify lapses and ensure accountability. Medical experts and consumer rights activists have called for stricter monitoring of pharmaceutical companies and more rigorous drug testing protocols to prevent such incidents. Public awareness campaigns are also being intensified to caution parents about the source and usage of over-the-counter medicines. The case has reignited debates on pharmaceutical regulation and the need for swift legal and administrative action to safeguard public health. #NagpurHospital #ColdrifCoughSyrup #ChhindwaraTragedy
A heartbreaking incident has shaken Nagpur after reports emerged on October 10, 2025, that several children admitted to a city hospital died after allegedly consuming toxic cough syrup. The syrup, believed to have been distributed through local pharmacies and smaller clinics, was found to contain harmful levels of diethylene glycol — a chemical known to cause kidney failure. Hospital sources confirmed multiple pediatric cases showing similar symptoms of poisoning, prompting the Maharashtra FDA to seal the remaining stock and begin an urgent recall. This tragedy mirrors earlier episodes of contaminated syrup deaths in India and abroad. In 2022, at least 66 children died in The Gambia after consuming Indian-manufactured cough syrup, sparking global scrutiny of drug safety standards. Similarly, in 2023, Tamil Nadu and Uttar Pradesh reported fatalities linked to spurious pediatric formulations. Despite repeated crackdowns, counterfeit or poorly regulated medicines continue to circulate through unlicensed distributors and small-scale manufacturers, exposing serious gaps in pharmaceutical oversight. Health officials in Nagpur have now launched a joint investigation involving the Food and Drug Administration (FDA), police, and the Health Department. Samples from the affected hospital have been sent to a Mumbai laboratory for testing, while the manufacturer’s license has been suspended pending results. Authorities have appealed to citizens to immediately stop using the identified brand and report any adverse reactions. Meanwhile, grief-stricken families and local activists are demanding stronger laws and stricter enforcement to prevent such tragedies from repeating. #NagpurHospital#CoughSyrupDeaths#ToxicMedicine#DrugSafety#PharmaScandal#PublicHealthCrisis#MaharashtraFDA#ChildSafety#MedicalNegligence#NagpurNews
